Your browser doesn't support javascript.
loading
System Accuracy Assessment of a Blood Glucose Meter With Wireless Internet Access Associated With Unusual Hypoglycemia Patterns in Clinical Trials.
Pfützner, Andreas; Demircik, Filiz; Kirsch, Valeria; Pfützner, Johannes; Strobl, Stephanie; Hanna, Mina; Spatz, Jan; Pfützner, Anke H.
Afiliación
  • Pfützner A; 1 Pfützner Science & Health Institute, Mainz, Germany.
  • Demircik F; 2 Sciema UG, Mainz, Germany.
  • Kirsch V; 3 Technical University Bonn-Rhein-Sieg, Rheinbach, Germany.
  • Pfützner J; 1 Pfützner Science & Health Institute, Mainz, Germany.
  • Strobl S; 2 Sciema UG, Mainz, Germany.
  • Hanna M; 1 Pfützner Science & Health Institute, Mainz, Germany.
  • Spatz J; 3 Technical University Bonn-Rhein-Sieg, Rheinbach, Germany.
  • Pfützner AH; 1 Pfützner Science & Health Institute, Mainz, Germany.
J Diabetes Sci Technol ; 13(3): 507-513, 2019 05.
Article en En | MEDLINE | ID: mdl-30974985
ABSTRACT

BACKGROUND:

In recent randomized clinical trials, an unusual reporting pattern of glycemic data and hypoglycemic events potentially related to an internet enabled blood glucose meter (MyGlucoHealth, BGM) was observed. Therefore, this clinical study was conducted to evaluate the system accuracy of the BGM in accordance with the ISO151972015 guidelines with additional data collection.

METHODS:

To investigate system accuracy, 10 of 3088 devices and 6 of 23 strip lots, used in the trials, were selected by a randomization procedure and a standard repeatability assessment. YSI 2300 STAT Plus was used as the standard reference method. The samples were distributed as per the ISO151972015 recommendations with 20 additional samples in the hypoglycemic range. Each sample was tested with 6 devices and 6 strip lots with double determinations.

RESULTS:

Overall, 121 subjects with blood glucose values 26-423 mg/dL were analyzed, resulting in 1452 data points. In all, 186/1452 readings (12.8%) did not meet the ISO acceptance criteria. Data evaluated according to the FDA guidelines showed that 336/1452 (23.1%) readings did not meet the acceptance criteria. A clear bias toward elevated values was observed for BG <100 mg/dL (MARD 11.0%).

CONCLUSIONS:

The results show that the BGM, although approved according to standard regulatory guidelines, did not meet the level of analytical accuracy required for clinical treatment decisions according to ISO 151972015 and FDA requirements. In general, caution should be exercised before selection of BGMs for patients and in clinical trials.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Glucemia / Ensayos Clínicos Controlados Aleatorios como Asunto / Diabetes Mellitus / Tecnología Inalámbrica / Acceso a Internet / Hipoglucemia Tipo de estudio: Clinical_trials / Diagnostic_studies / Guideline / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male / Middle aged Idioma: En Revista: J Diabetes Sci Technol Asunto de la revista: ENDOCRINOLOGIA Año: 2019 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Glucemia / Ensayos Clínicos Controlados Aleatorios como Asunto / Diabetes Mellitus / Tecnología Inalámbrica / Acceso a Internet / Hipoglucemia Tipo de estudio: Clinical_trials / Diagnostic_studies / Guideline / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male / Middle aged Idioma: En Revista: J Diabetes Sci Technol Asunto de la revista: ENDOCRINOLOGIA Año: 2019 Tipo del documento: Article País de afiliación: Alemania